LV11631B - Humanized antibodies and uses thereof - Google Patents
Humanized antibodies and uses thereof Download PDFInfo
- Publication number
- LV11631B LV11631B LVP-96-218A LV960218A LV11631B LV 11631 B LV11631 B LV 11631B LV 960218 A LV960218 A LV 960218A LV 11631 B LV11631 B LV 11631B
- Authority
- LV
- Latvia
- Prior art keywords
- sequence
- celis
- antibody
- celi
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1 LV 11631 Izgudrojuma formula 1. Cilvēkam piemērota antiviela vai tajā ietilpstošā antigēnu saistošā olbaltumviela ar tādu aminoskābju secību, kas ietver visu vai daļu no tās aminoskābju secības, kura pamatā ietilpst komplimentaritāti nosakošos apgabalos monoklonālajā antivielā ar specifisku saistību pret noteiktu T šūnu subpopulāciju, kas ekspresē mainīgos T šūnu antigēna receptora beta-ķēdes apgabalus νβ5.2 vai νβ5.3, saistībā ar dažādiem izmeklētiem olbaltumvielas fragmentiem no minētās monoklonālās antivielas, pie kam antiviela vai tajā ietilpstošā antigēnu saistošā olbaltumviela spēj saistīties ar minētajām noteiktajām T šūnu subpopulācijām vismaz ar tikpat lielu afinitāti, kā minētā monoklonālā antiviela, pie kam cilvēkam piemērotā antiviela vai tajā ietilpstošā antigēnu saistošā olbaltumviela satur aminoskābju secību TM27 Vk: 1 DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQTPGKAPKLLIYY 50 51 TSSLHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYSKLPRTFGQ 100 101 GTKLOIT 107 un papildus tai satur aminoskābju secību, kas ņemta no šādas secību grupas: secība TM27 VH 1 QVQLQESGPGLVRPSQTLSLTCTVSGFSLTAYGVNWVROPPGRGLEWLGM 50 51 IWGDGNTDYNSALKSRVTMLKDTSKNQKSLRLSSVTAADTAVYYCARDRV 100 101 TATLYAMDYWGQGSLVTVSS 120 2 secība TM27 VH, kurā 48. aminoskābes atlikums aizvietots ar izoleicīna atlikumu (I); secība TM27 VH, kurā 78. un 79. aminoskābju atlikumi ir vafīns (V) un fenilalanīns (F); secība TM27 VHl kurā aminoskābju atlikumi no 67. līdz 70. ar secību VTML ir attiecīgi aizvietoti ar secību LSIS, bet 73. aminoskābes atlikums ir asparagīns (N); secība TM27VH, kurā 92. aminoskābes atlikums ir arginīns (R).
2. Cilvēkam piemērota antiviela vai tajā ietilpstošā antigēnu saistošā olbaltumviela ar tādu aminoskābju secību, kas ietver visu vai daju no tās aminoskābju secības, kura pamatā ietilpst komplimentaritāti nosakošos apgabalos monoklonālajā antivielā ar specifisku saistību pret noteiktu T šūnu subpopulāciju, kas ekspresē mainīgo T šūnu antigēna receptora beta-ķēdes apgabalu νβ8.1, saistībā ar dažādiem izmeklētiem olbaltumvielas fragmentiem no minētās monoklonālās antivielas, pie kam antiviela vai tajā ietilpstošā antigēnu saistošā olbaltumviela spēj saistīties ar minētajām noteiktajām T šūnu subpopulācijām vismaz ar tikpat lielu afinitāti, kā minētā monoklonālā antiviela, pie kam cilvēkam piemērotā antiviela vai tajā ietilpstošā antigēnu saistošā olbaltumviela satur aminoskābju secību TM29 Vk: 1 DIQMTQSPSSLSASVGDRVTITCRASSSVNYIYWYQQTPGKAPKLLIYYT 50 51 SNLAPGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQQFTSSPFTFGQGT 100 101 KLQIT 106. un papildus tai satur aminoskābju secību, kas ņemta no šādas secību grupas: secība TM29 VH 1 EVQLVESGGGWQPGRSLRLSCSSSGFTFSNFGMHWVRQAPGKGLEWVAY 50 51 ISSGSSTIYYADTLKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARRG 100 101 EGAMDYWGQGTPVTVSS 117. 3 3 LV 11631 secība TM29 VH) kurā 23. un 24. aminoskābju atlikumi abi aizvietoti ar alanīna atlikumu (A); secība TM29 VHl kurā 75. aminoskābes atlikums ir aizvietots ar prolīna atlikumu (P); secība TM29 VH, kurā aminoskābju atlikumi 92. un 93. aizvietoti, attiecīgi, ar alanīna (A) un metionīna (M) atlikumu, bet 95. aminoskābes atlikums ir aizvietots ar tirozīna (Y) atlikumu.
3. Cilvēkam piemērota antiviela pēc 1. vai 2. punkta, kas veido izotipa lgG2a secību.
4. Cilvēkam piemērota antiviela pēc 3. punkta, kurā izmainītas viena vai vairākas aminoskābes konstantajos Ig domēnos ar nolūku izmainīt minētā konstantā domēna efektora funkciju.
5. Cilvēkam piemērota antiviela vai tajā ietilpstošā antigēnu saistošā olbaltumviela pēc 1. vai 2. punkta, kas iegūta ar rekombinatās DNS tehnoloģiju.
6. Paņēmiens cilvēkam piemērotas antivielas vai tajā ietilpstošās antigēnu saistošās olbaltumvielas pēc jebkura no iepriekšējiem punktiem iegūšanai, kas paredz: a) izolēt pirmo DNS secību, kas pamatā kodē vismaz vienu komplimentaritāti nosakošo apgabalu peles monoklonālajā antivielā anti-νβ5.2Λ/β5.3 vai anti-\^8.1 ar specifisku saistību pret noteiktu T šūnu subpopulāciju; b) klonēt minēto pirmo DNS secību piemērotā vektorā: c) ar mutaģenēzi ievadīt izmeklētas cilvēka olbaltumvielas aminoskābes, nolūkā izveidot konstrukciju, kurā iesaistīti komplimentaritāti nosakošie apgabali; d) transformēt saimniekšūnu ar posmā c) iegūto konstrukciju; 4 e) kultivēt minēto transformēto saimniekšūnu, lai producētu minēto cilvēkam piemēroto antivielu vai tajā ietilpstošo antigēnu saistošo olbaltumvielu.
7. Paņēmiens pēc 6. punkta, kurā saimniekšūna ir CHO šūna.
8. Cilvēkam piemērotā antiviela vai tajā ietilpstošā antigēnu saistošā olbaltumviela pēc 1. vai 2. punkta pielietojumam ārstniecībā.
9. Farmaceitiskā kompozīcija, kas satur cilvēkam piemēroto antivielu vai tajā ietilpstošo antigēnu saistošo olbaltumvielu pēc 1. vai 2. punkta kopā ar farmaceitiski pieņemamu atšķaidītāju.
10. Cilvēkam piemērotās antivielas vai tajā ietilpstošās antigēnu saistošās olbaltumvielas pēc 1. vai 2. punkta pielietojums tāda medikamenta ražošanai, kas paredzēts Krona (Crohn) slimības ārstēšanai.
11. Cilvēkam piemērotās antivielas vai tajā ietilpstošās antigēnu saistošās olbaltumvielas pēc 1. vai 2. punkta pielietojums tāda medikamenta ražošanai, kas paredzēts multiplās sklerozes ārstēšanai.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939325182A GB9325182D0 (en) | 1993-12-08 | 1993-12-08 | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
| PCT/IB1994/000387 WO1995016038A2 (en) | 1993-12-08 | 1994-11-21 | Humanized antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV11631A LV11631A (lv) | 1996-12-20 |
| LV11631B true LV11631B (en) | 1997-04-20 |
Family
ID=10746330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-96-218A LV11631B (en) | 1993-12-08 | 1996-07-04 | Humanized antibodies and uses thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5861155A (lv) |
| EP (1) | EP0737250A1 (lv) |
| JP (1) | JPH09509307A (lv) |
| KR (2) | KR100239607B1 (lv) |
| CN (1) | CN1063792C (lv) |
| AU (1) | AU699249B2 (lv) |
| BR (1) | BR9408278A (lv) |
| CA (1) | CA2178622A1 (lv) |
| CZ (2) | CZ287347B6 (lv) |
| EE (1) | EE03271B1 (lv) |
| FI (1) | FI962377A (lv) |
| GB (1) | GB9325182D0 (lv) |
| HU (1) | HUT75553A (lv) |
| IL (1) | IL111926A (lv) |
| LV (1) | LV11631B (lv) |
| NO (1) | NO962346L (lv) |
| NZ (1) | NZ276170A (lv) |
| PL (1) | PL180157B1 (lv) |
| RU (1) | RU2139934C1 (lv) |
| SG (1) | SG48420A1 (lv) |
| SK (1) | SK73596A3 (lv) |
| UA (1) | UA29494C2 (lv) |
| WO (1) | WO1995016038A2 (lv) |
| ZA (1) | ZA949341B (lv) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6348581B1 (en) * | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
| CN1064052C (zh) * | 1997-09-29 | 2001-04-04 | 中国科学院微生物研究所 | 甲状旁腺素相关蛋白人源化抗体及其制备方法 |
| AU2444899A (en) * | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| GB9906233D0 (en) * | 1999-03-19 | 1999-05-12 | Univ Newcastle | Bone formation |
| EP1326991A2 (en) * | 2000-10-20 | 2003-07-16 | Whitehead Institute For Biomedical Research | Expression vectors and uses thereof |
| US20060233790A1 (en) * | 2002-03-22 | 2006-10-19 | Shiroh Futaki | Immunoglobulin/hydrophilic peptide complexes |
| US7794716B2 (en) | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
| GB0302740D0 (en) * | 2003-02-06 | 2003-03-12 | Axis Shield Asa | Assay |
| US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| US8008442B2 (en) * | 2004-04-22 | 2011-08-30 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| US7741448B2 (en) * | 2005-06-21 | 2010-06-22 | Medical & Biological Laboratories Co., Ltd. | Antibody having inhibitory effect on amyloid fibril formation |
| KR100740201B1 (ko) * | 2005-10-21 | 2007-07-18 | 삼성전자주식회사 | 듀얼 전송 스트림 생성 장치 및 그 방법 |
| US20080213274A1 (en) * | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
| US20090074720A1 (en) * | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
| WO2007125089A2 (en) * | 2006-04-28 | 2007-11-08 | ETH Zürich | Antibodies for the detection of bacillus anthracis and vaccine against b. anthracis infections |
| US7862812B2 (en) * | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
| CA2656347A1 (en) | 2006-07-03 | 2008-01-10 | Charles David Adair | Composition for modulating the expression of cell adhesion molecules |
| US8444970B2 (en) * | 2006-10-27 | 2013-05-21 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
| PT2087002E (pt) * | 2006-10-27 | 2014-11-26 | Lpath Inc | Composições e métodos para a ligação de esfingosina-1- fosfato |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US8158124B2 (en) * | 2007-05-30 | 2012-04-17 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US8604172B2 (en) * | 2009-04-17 | 2013-12-10 | Lpath, Inc. | Humanized antibody compositions and methods for binding lysophosphatidic acid |
| US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| JP2010535503A (ja) | 2007-08-10 | 2010-11-25 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ（エー＊エスティーエーアール） | 癌の診断および治療のためのｖｈｚ |
| BRPI0817257A2 (pt) * | 2007-09-24 | 2015-06-16 | Univ Vanderbilt | Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos |
| US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
| CN102176914B (zh) * | 2008-08-08 | 2014-12-17 | 新加坡科技研究局 | 用于诊断和治疗癌症的vhz |
| US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| CA2745111A1 (en) | 2008-12-03 | 2010-06-10 | Research Development Foundation | Modulation of olfml-3 mediated angiogenesis |
| US8401799B2 (en) * | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
| CN102573905A (zh) * | 2008-12-05 | 2012-07-11 | 勒帕斯公司 | 利用抗脂类抗体晶体结构的抗体设计 |
| US20100292443A1 (en) * | 2009-02-26 | 2010-11-18 | Sabbadini Roger A | Humanized platelet activating factor antibody design using anti-lipid antibody templates |
| CA2790200A1 (en) | 2010-02-19 | 2011-08-25 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof |
| US20110212088A1 (en) * | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
| RU2603097C2 (ru) | 2010-12-21 | 2016-11-20 | Селексис Фармасьютикалс Корпорейшн | Антитела к р-селектину и способы их применения и идентификации |
| CA2858350A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| WO2012129520A1 (en) | 2011-03-24 | 2012-09-27 | Texas Tech University System | Tcr mimic antibodies as vascular targeting tools |
| EP2710037B1 (en) | 2011-05-19 | 2019-07-31 | The Regents of The University of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
| AU2012294814A1 (en) | 2011-08-05 | 2014-02-27 | Research Development Foundation | Improved methods and compositions for modulation of Olfml3 mediated angiogenesis |
| EP3718556A3 (en) | 2012-08-31 | 2020-12-30 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| AU2013312529A1 (en) | 2012-09-05 | 2015-04-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
| AU2013334583B2 (en) | 2012-10-24 | 2018-09-13 | Research Development Foundation | JAM-C antibodies and methods for treatment of cancer |
| EP3756687A3 (en) | 2012-12-13 | 2021-03-24 | University Of Virginia Patent Foundation | Target peptides for ovarian cancer therapy and diagnostics |
| EP2978440B1 (en) | 2013-03-27 | 2019-10-02 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra |
| US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
| CN114621346A (zh) | 2013-08-21 | 2022-06-14 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
| MA45352A (fr) | 2015-08-07 | 2018-06-13 | Univ Birmingham | Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer |
| EP3909983A1 (en) | 2015-12-02 | 2021-11-17 | STCube & Co. Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| EP3383908A1 (en) | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
| WO2017147561A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Texas System | CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF |
| CN118773299A (zh) | 2016-03-17 | 2024-10-15 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| WO2017172518A1 (en) | 2016-03-29 | 2017-10-05 | Stcube, Inc. | Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof |
| CN109195990A (zh) | 2016-03-30 | 2019-01-11 | Musc研究发展基金会 | 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法 |
| US11746152B2 (en) | 2016-07-20 | 2023-09-05 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1 |
| KR20190082815A (ko) | 2016-10-26 | 2019-07-10 | 세다르스-신나이 메디칼 센터 | 중화 항-tl1a 단일 클론 항체 |
| JP7169298B2 (ja) | 2017-05-12 | 2022-11-10 | オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド | ヒトアルファフェトタンパク質特異的ｔ細胞受容体およびその使用 |
| EP3630835A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| KR20200024158A (ko) | 2017-05-31 | 2020-03-06 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법 |
| US11542331B2 (en) | 2017-06-06 | 2023-01-03 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands |
| CN117050176A (zh) | 2017-07-31 | 2023-11-14 | 豪夫迈·罗氏有限公司 | 基于三维结构的人源化方法 |
| DE112018005145T5 (de) | 2017-09-15 | 2020-07-23 | The Regents Of The University Of California | Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs |
| WO2019195561A2 (en) | 2018-04-06 | 2019-10-10 | BioLegend, Inc. | Anti-tetraspanin 33 agents and compositions and methods for making and using the same |
| JP7332627B2 (ja) | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN113365697B (zh) | 2018-09-25 | 2024-07-19 | 百进生物科技公司 | 抗tlr9药剂和组合物及其制备方法和使用方法 |
| KR20210108363A (ko) | 2018-11-02 | 2021-09-02 | 오클라호마 메디컬 리써치 화운데이션 | Eltd1에 대한 단일클론성 항체 및 이의 용도 |
| WO2020172601A1 (en) * | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN114127112A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| US20220411511A1 (en) | 2019-09-26 | 2022-12-29 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
| EP4041768A1 (en) | 2019-10-09 | 2022-08-17 | StCube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
| JP7504992B2 (ja) | 2019-10-24 | 2024-06-24 | プロメテウス バイオサイエンシーズ，インク． | Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用 |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| CN115427447A (zh) | 2020-01-17 | 2022-12-02 | 百进生物科技公司 | 抗tlr7药剂和组合物以及制备和使用其的方法 |
| CA3168337A1 (en) | 2020-02-17 | 2021-08-26 | Marie-Andree Forget | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| JP2023523011A (ja) | 2020-04-24 | 2023-06-01 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| CA3190755A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20230074487A (ko) | 2020-08-26 | 2023-05-30 | 마렝고 테라퓨틱스, 인크. | Trbc1 또는 trbc2를 검출하는 방법 |
| WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
| WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
| US20240002541A1 (en) | 2020-12-01 | 2024-01-04 | The Johns Hopkins University | Methods and materials for treating t cell cancers |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| WO2024020051A1 (en) | 2022-07-19 | 2024-01-25 | BioLegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
| WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) * | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5426029A (en) * | 1986-03-31 | 1995-06-20 | T Cell Diagnostics, Inc. | Therapeutic and diagnostic methods using leukocyte surface antigens |
| JP3095168B2 (ja) * | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| EP0328404B1 (en) * | 1988-02-12 | 1993-09-29 | Btg International Limited | Modified antibodies |
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| US5766947A (en) * | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| CA2018248A1 (en) * | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| WO1991001133A1 (en) * | 1989-07-19 | 1991-02-07 | Arthur Allen Vandenbark | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5067193A (en) * | 1990-07-26 | 1991-11-26 | Container Graphics Corporation | Rotary printing plate washing apparatus |
| US5445940A (en) * | 1991-08-28 | 1995-08-29 | Brigham & Women's Hospital | Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease |
-
1993
- 1993-12-08 GB GB939325182A patent/GB9325182D0/en active Pending
-
1994
- 1994-11-21 CA CA002178622A patent/CA2178622A1/en not_active Abandoned
- 1994-11-21 AU AU10333/95A patent/AU699249B2/en not_active Ceased
- 1994-11-21 RU RU96115107A patent/RU2139934C1/ru active
- 1994-11-21 WO PCT/IB1994/000387 patent/WO1995016038A2/en not_active Application Discontinuation
- 1994-11-21 CZ CZ19961628A patent/CZ287347B6/cs not_active IP Right Cessation
- 1994-11-21 SK SK735-96A patent/SK73596A3/sk unknown
- 1994-11-21 SG SG1996009542A patent/SG48420A1/en unknown
- 1994-11-21 BR BR9408278A patent/BR9408278A/pt not_active Application Discontinuation
- 1994-11-21 UA UA96072682A patent/UA29494C2/uk unknown
- 1994-11-21 US US08/652,558 patent/US5861155A/en not_active Expired - Fee Related
- 1994-11-21 JP JP7516077A patent/JPH09509307A/ja active Pending
- 1994-11-21 EE EE9600108A patent/EE03271B1/xx unknown
- 1994-11-21 HU HU9601574A patent/HUT75553A/hu unknown
- 1994-11-21 EP EP95900892A patent/EP0737250A1/en not_active Withdrawn
- 1994-11-21 CN CN94194971A patent/CN1063792C/zh not_active Expired - Fee Related
- 1994-11-21 KR KR1019960703068A patent/KR100239607B1/ko not_active IP Right Cessation
- 1994-11-24 ZA ZA949341A patent/ZA949341B/xx unknown
- 1994-12-07 IL IL11192694A patent/IL111926A/en not_active IP Right Cessation
-
1996
- 1996-06-05 NO NO962346A patent/NO962346L/no not_active Application Discontinuation
- 1996-06-07 FI FI962377A patent/FI962377A/fi unknown
- 1996-07-04 LV LVP-96-218A patent/LV11631B/en unknown
- 1996-08-07 NZ NZ276170A patent/NZ276170A/en unknown
- 1996-08-07 PL PL94314908A patent/PL180157B1/pl unknown
-
1998
- 1998-01-27 CZ CZ1998236A patent/CZ287298B6/cs not_active IP Right Cessation
-
1999
- 1999-03-02 KR KR1019997001727A patent/KR100258902B1/ko not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5861155A (en) | Humanized antibodies and uses thereof | |
| EP0460178B1 (en) | Cd4 specific recombinant antibody | |
| KR101685262B1 (ko) | 항-ｏｘ４０ 항체 및 이의 사용 방법 | |
| KR100249937B1 (ko) | 인간 인터루킨-6 수용체에 대한 재구성 인간 항체 | |
| RU2342401C2 (ru) | Антитела, специфичные к cd22 человека, и их применения в терапии и диагностике | |
| US20030103976A1 (en) | Anti-fas antibodies | |
| JP2010183907A (ja) | 組換え抗ｖｌａ４抗体分子 | |
| US20020099179A1 (en) | Cdr-grafted antibodies | |
| JP2023516286A (ja) | グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法 | |
| EP0856009A1 (en) | Cd6 ligand | |
| WO2024173607A2 (en) | Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment | |
| JP2023504974A (ja) | 抗ｔｉｒｃ７抗原結合タンパク質 | |
| JP2000166574A (ja) | ヒト化抗Ｆａｓ抗体 | |
| JP2000169393A (ja) | 抗Ｆａｓ抗体を含有する医薬 | |
| JPH11171900A (ja) | 抗Ｆａｓ抗体 | |
| JP2000166573A (ja) | ヒト化抗Ｆａｓ抗体 | |
| MXPA98002536A (en) | Antibodies anti- | |
| JP2001342149A (ja) | ヒト化抗Ｆａｓ抗体を含有する医薬 |